{"id":"https://openalex.org/W4411289999","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p1-06-09","title":"Abstract P1-06-09: Importance of Assessing Thyroid Dysfunction in Breast Cancer Patients Undergoing Pembrolizumab-based Neoadjuvant Chemotherapy","display_name":"Abstract P1-06-09: Importance of Assessing Thyroid Dysfunction in Breast Cancer Patients Undergoing Pembrolizumab-based Neoadjuvant Chemotherapy","publication_year":2025,"publication_date":"2025-06-13","ids":{"openalex":"https://openalex.org/W4411289999","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p1-06-09"},"language":"en","primary_location":{"id":"doi:10.1158/1557-3265.sabcs24-p1-06-09","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p1-06-09","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs24-p1-06-09","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072966032","display_name":"Byeongju Kang","orcid":"https://orcid.org/0000-0002-3589-5559","observed_orcids":["https://orcid.org/0000-0002-3589-5559"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Byeongju Kang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101519605","display_name":"Jung Eun Choi","orcid":"https://orcid.org/0000-0003-2290-6228","observed_orcids":["https://orcid.org/0000-0003-2290-6228"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jung Eun Choi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Moohyun Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Moohyun Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071557112","display_name":"Ho Yong Park","orcid":"https://orcid.org/0000-0002-4380-0089","observed_orcids":["https://orcid.org/0000-0002-4380-0089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ho Yong Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012145865","display_name":"Jin Hyang Jung","orcid":"https://orcid.org/0000-0003-2607-1686","observed_orcids":["https://orcid.org/0000-0003-2607-1686"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin Hyang Jung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084299599","display_name":"Soo Jung Lee","orcid":"https://orcid.org/0000-0003-0066-4109","observed_orcids":["https://orcid.org/0000-0003-0066-4109","https://orcid.org/0000-0002-0139-9768"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Soo Jung Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103163012","display_name":"Su Hwan Kang","orcid":"https://orcid.org/0000-0001-7044-9311","observed_orcids":["https://orcid.org/0000-0001-7044-9311"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Su Hwan Kang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101453039","display_name":"Jin Gu Kang","orcid":"https://orcid.org/0000-0002-3154-0697","observed_orcids":["https://orcid.org/0000-0002-3154-0697"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jin Gu Kang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102994042","display_name":"Sun Hee Kang","orcid":"https://orcid.org/0000-0002-2155-3785","observed_orcids":["https://orcid.org/0000-0002-2155-3785"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sun Hee Kang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008707514","display_name":"Jihyoung Cho","orcid":"https://orcid.org/0000-0002-1680-2919","observed_orcids":["https://orcid.org/0000-0002-1680-2919"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jihyoung Cho","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109170456","display_name":"Yee Soo Chae","orcid":"https://orcid.org/0000-0002-8585-4982","observed_orcids":["https://orcid.org/0000-0002-8585-4982","https://orcid.org/0000-0002-4420-4035"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yee Soo Chae","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084299599","display_name":"Soo Jung Lee","orcid":"https://orcid.org/0000-0003-0066-4109","observed_orcids":["https://orcid.org/0000-0003-0066-4109","https://orcid.org/0000-0002-0139-9768"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Soo Jung Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"In-Hee Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"In-Hee Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042276732","display_name":"Keon Uk Park","orcid":"https://orcid.org/0000-0002-6902-7063","observed_orcids":["https://orcid.org/0000-0002-6902-7063"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keon Uk Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079402938","display_name":"Hyera Kim","orcid":"https://orcid.org/0000-0002-5590-5099","observed_orcids":["https://orcid.org/0000-0002-5590-5099"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hyera Kim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5100600136","display_name":"Jeeyeon Lee","orcid":"https://orcid.org/0000-0003-3995-5747","observed_orcids":["https://orcid.org/0000-0003-3995-5747"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeeyeon Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"31","issue":"12_Supplement","first_page":"P1","last_page":"06"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8500999808311462,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8500999808311462,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.12479999661445618,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10293","display_name":"Thyroid Disorders and Treatments","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9440000057220459},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8619999885559082},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":0.9319999814033508},{"id":"https://openalex.org/keywords/keynote-522","display_name":"KEYNOTE-522","score":0.9120000004768372},{"id":"https://openalex.org/keywords/thyroid-disease","display_name":"thyroid dysfunction","score":0.5649999976158142},{"id":"https://openalex.org/keywords/hypothyroidism","display_name":"hypothyroidism","score":0.6470000147819519},{"id":"https://openalex.org/keywords/hyperthyroidism","display_name":"hyperthyroidism","score":0.7789999842643738},{"id":"https://openalex.org/keywords/fatal-adverse-events","display_name":"fatal adverse events","score":0.4189999997615814},{"id":"https://openalex.org/keywords/colitis","display_name":"colitis","score":0.746999979019165},{"id":"https://openalex.org/keywords/pneumonitis","display_name":"pneumonitis","score":0.996999979019165},{"id":"https://openalex.org/keywords/dermatologic-adverse-events","display_name":"dermatologic adverse events","score":0.6610000133514404},{"id":"https://openalex.org/keywords/endocrine-adverse-events","display_name":"endocrine adverse events","score":0.5870000123977661},{"id":"https://openalex.org/keywords/general-anesthesia","display_name":"general anesthesia","score":0.375},{"id":"https://openalex.org/keywords/preoperative-assessment","display_name":"preoperative assessment","score":0.4309999942779541},{"id":"https://openalex.org/keywords/pcr","display_name":"PCR","score":0.3619999885559082},{"id":"https://openalex.org/keywords/immunotherapy-safety","display_name":"immunotherapy safety","score":0.4749999940395355}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8900731801986694},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.808650016784668},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.7423912286758423},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.7002514600753784},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6364201903343201},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.48888105154037476},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45703402161598206},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.4255765676498413},{"id":"https://openalex.org/C526584372","wikidata":"https://www.wikidata.org/wiki/Q16399","display_name":"Thyroid","level":2,"score":0.42060843110084534},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.08126625418663025}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1557-3265.sabcs24-p1-06-09","doi":"https://doi.org/10.1158/1557-3265.sabcs24-p1-06-09","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1557-3265.sabcs24-p1-06-09","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7135099182","https://openalex.org/W4411289187","https://openalex.org/W4399324203","https://openalex.org/W7162652216","https://openalex.org/W7161989781","https://openalex.org/W4409328706","https://openalex.org/W4401358661","https://openalex.org/W4388638630","https://openalex.org/W7125539253","https://openalex.org/W4411290424"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"Pembrolizumab":[2],"is":[3,34],"a":[4,84],"novel":[5],"immunotherapy":[6],"agent":[7],"that":[8,47,70,121,138,148,352,365],"improves":[9],"oncological":[10],"outcomes":[11],"in":[12,252,358,380,394,445],"various":[13,27],"cancer":[14,63,145],"types.":[15],"Although":[16],"there":[17],"are":[18],"minor":[19],"immune-related":[20],"adverse":[21,204,210,290],"events":[22,211],"(irAEs)":[23],"when":[24,32],"used":[25],"alone,":[26],"irAEs":[28,46,69,120,272,351],"have":[29],"been":[30],"reported":[31],"it":[33],"combined":[35],"with":[36,53,95,192,300,356],"chemotherapy.":[37],"The":[38,155,329,350],"aims":[39],"of":[40,143,158,209,265,314,346,373,441,456],"this":[41],"study":[42],"were":[43,112,123,152,171,212,227,236,286,309,338,360,366],"to":[44,66,317,340,369,391],"investigate":[45],"occurred":[48,122,149,251,353],"after":[49,150,273,292,343,354],"neoadjuvant":[50,389],"chemotherapy":[51,390],"(NAC)":[52],"pembrolizumab":[54,96,103,276,357],"based":[55,97,114],"on":[56,98,115],"the":[57,141,159,167,194,207,228,237,287,298,319,371,388,457],"KEYNOTE-522":[58,99],"regimen":[59,100],"for":[60,277,311],"triple-negative":[61],"breast":[62,144],"(TNBC)":[64],"and":[65,82,102,107,125,134,166,186,206,221,233,248,256,275,295,362,385],"identify":[67],"fatal":[68,244,271,305],"should":[71,382],"be":[72,383],"corrected":[73,386],"before":[74,140,322],"surgery":[75,111,151,342,374],"under":[76,375],"general":[77,327,376],"anesthesia.":[78,328,377],"Methods:":[79],"Between":[80],"2022":[81],"2024,":[83],"total":[85],"of,":[86],"71":[87],"cases":[88],"from":[89],"81":[90],"patients":[91,160,201,254,258,299],"who":[92,332],"completed":[93],"NAC":[94,191,274,355],"(wP/Cab":[101],"followed":[104,109],"by":[105,110],"AC":[106],"pembrolizumab)":[108],"reviewed":[113],"their":[116],"medical":[117],"records.":[118],"All":[119],"investigated":[124],"classified":[126],"into":[127],"five":[128],"categories:":[129],"systemic,":[130],"gastrointestinal,":[131],"respiratory,":[132],"musculoskeletal,":[133],"endocrine.":[135],"Underlying":[136],"diseases":[137],"existed":[139],"diagnosis":[142,170],"or":[146,268],"complications":[147],"excluded.":[153],"Results:":[154],"mean":[156],"age":[157],"was":[161,197,262],"49.62":[162],"(SD,":[163],"\u00b110.6)":[164],"years,":[165],"stages":[168],"at":[169],"as":[172,213,270],"follows:":[173,214],"IIA":[174],"(n=23,":[175],"32.4%),":[176],"IIB":[177],"(n=22,":[178,223],"31.0%),":[179],"IIIA":[180],"(n=14,":[181],"16.2%),":[182],"IIIB":[183],"(n=1,":[184],"1.4%),":[185],"IIIC":[187],"(n=11,":[188,216],"15.5%).":[189],"After":[190],"pembrolizumab,":[193],"pCR":[195],"rate":[196],"49.3%":[198],"(35/71)":[199],"Fifty-three":[200],"(62.2%)":[202],"experienced":[203,304],"events,":[205],"number":[208],"1":[215],"20.8%),":[217],"2":[218,257],"(n=20,":[219],"37.7%),":[220],"\u22653":[222],"41.5%).":[224],"Gastrointestinal":[225],"symptoms":[226,235],"most":[229,239,288],"common":[230,240,289],"(n=46,":[231],"86.8%),":[232],"dermatologic":[234],"second":[238],"(n=31,":[241],"58.5%).":[242],"Among":[243,279],"irAEs,":[245,281],"including":[246],"colitis":[247],"pneumonitis,":[249],"they":[250,323],"11":[253],"(20.8%)":[255],"(3.8%),":[259],"respectively.":[260],"There":[261],"no":[263],"case":[264],"hepatitis,":[266],"myocarditis,":[267],"hypophysitis":[269],"TNBC.":[278],"these":[280],"thyroid":[282,301,320],"disorders":[283],"(n=16,":[284],"22.5%)":[285],"event":[291],"skin":[293],"rash":[294],"nausea.":[296],"Of":[297],"disorders,":[302],"3":[303],"dysfunction.":[306],"Their":[307],"surgeries":[308],"delayed":[310],"an":[312,344],"average":[313,345],"8.5":[315],"weeks":[316],"correct":[318],"imbalance":[321],"could":[324],"safely":[325],"undergo":[326,341],"remaining":[330],"patients,":[331],"did":[333],"not":[334],"experience":[335],"such":[336],"complications,":[337],"able":[339],"5.2":[347],"weeks.":[348],"Conclusion:":[349],"TNBC":[359],"varied":[361],"included":[363],"some":[364],"severe":[367],"enough":[368],"affect":[370],"timing":[372],"Thyroid":[378,443],"dysfunction,":[379],"particular,":[381],"evaluated":[384],"during":[387],"prevent":[392],"delays":[393],"surgery.":[395],"Citation":[396],"Format:":[397],"Byeongju":[398],"Kang,":[399,416,419,422],"Jung":[400,412,429],"Eun":[401],"Choi,":[402],"Moohyun":[403],"Lee,":[404,413,430,432],"Ho":[405],"Yong":[406],"Park,":[407,435],"Jin":[408,417],"Hyang":[409],"Jung,":[410],"Soo":[411,426,428],"Su":[414],"Hwan":[415],"Gu":[418],"Sun":[420],"Hee":[421],"Jihyoung":[423],"Cho,":[424],"Yee":[425],"Chae,":[427],"In-Hee":[431],"Keon":[433],"Uk":[434],"Hyera":[436],"Kim,":[437],"Jeeyeon":[438],"Lee.":[439],"Importance":[440],"Assessing":[442],"Dysfunction":[444],"Breast":[446,460],"Cancer":[447,461,474],"Patients":[448],"Undergoing":[449],"Pembrolizumab-based":[450],"Neoadjuvant":[451],"Chemotherapy":[452],"[abstract].":[453],"In:":[454],"Proceedings":[455],"San":[458,467],"Antonio":[459],"Symposium":[462],"2024;":[463],"2024":[464],"Dec":[465],"10-13;":[466],"Antonio,":[468],"TX.":[469],"Philadelphia":[470],"(PA):":[471],"AACR;":[472],"Clin":[473],"Res":[475],"2025;31(12":[476],"Suppl):Abstract":[477],"nr":[478],"P1-06-09.":[479]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}